CoChat

Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease

Hayward, Rodney A., Krumholz, Harlan M., Zulman, Donna M., Timbie, Justin W., Vijan, Sandeep · 2010 · Annals of Internal Medicine
Cited by 132

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Although treating to lipid targets ("treat to target") is widely recommended for coronary artery disease (CAD) prevention, some have advocated administering fixed doses of statins based on a person's estimated net benefit ("tailored treatment"). OBJECTIVE: To examine how a tailored treatment approach to statin therapy compares with a treat-to-target approach. DESIGN: Simulated model of population-level effects of treat-to-target and tailored treatment approaches to statin therapy. DATA SOURCES: Statin trials from 1994 to 2009 and nationally representative CAD risk factor data. TARGET POPULATION: U.S. persons aged 30 to 75 years with no history of myocardial infarction. TIME HORIZON: Lifetime effects of 5 years of treatment. PERSPECTIVE: Societal and patient. INTERVENTION: Tailored treatment based on a person's 5-year CAD risk (simvastatin, 40 mg, for 5% to 15% CAD risk and atorvastatin, 40 mg, for CAD risk >15%) versus treat-to-target approaches that escalate statin dose per National Cholesterol Education Program [NCEP] III guidelines (including an intensive approach that advances treatment whenever intensification is optional by NCEP III criteria). OUTCOME MEASURES: Quality-adjusted life-years (QALYs). RESULTS OF BASE-CASE ANALYSIS: Compared with the standard NCEP III approach, the intensive NCEP III approach treated 15 million more persons and saved 570,000 more QALYs over 5 years. The tailored strategy treated a similar number of persons, as did the intensive NCEP III approach, but saved 500,000 more QALYs and treated fewer persons with high-dose statins. RESULTS OF SENSITIVITY ANALYSIS: No circumstances were found in which a treat-to-target approach was preferable to tailored treatment. LIMITATION: Model assumptions were based on available clinical data, which included few persons 75 years or older. CONCLUSION: A tailored treatment strategy prevents more CAD events while treating fewer persons with high-dose statins than low-density lipoprotein cholesterol-based target approaches. Results were robust, even with assumptions favoring a treat-to-target approach. PRIMARY FUNDING SOURCE: Department of Veteran Affairs Health Services Research & Development Service's Quality Enhancement Research Initiative.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-152-2-201001190-00004

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 132

Metadata

Authors
Hayward, R. A., Krumholz, H. M., Zulman, D. M., Timbie, J. W., & Vijan, S.
Venue
Annals of Internal Medicine
Published
2010-01-19
Volume
152
Issue
2
Pages
69-77
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2045440979
Cited by
132
References
16
FWCI
23.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease. https://app.cochat.ai/papers/10.7326/0003-4819-152-2-201001190-00004
The paper
Hayward, R. A., Krumholz, H. M., Zulman, D. M., Timbie, J. W., & Vijan, S. (2010). Optimizing Statin Treatment for Primary Prevention of Coronary Artery Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-152-2-201001190-00004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.